ClinicalTrials.gg
CompletedNCT04086550ENCASE-IIUpdated Jun 26, 2024

Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery

An interventional study of LIQOSEAL and DuraSeal, Adherus in Cerebrospinal Fluid Leak, sponsored by Polyganics BV. Completed at 17 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Polyganics BV · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cerebrospinal Fluid Leak with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Cerebrospinal Fluid Leak · United States.

Started
2021
with 1 other
No phase
3 of 12
1 open now
Registered
7th of 12
by date
Lead sponsor
1 of 12
Polyganics BV

Among the 12 studies in Cerebrospinal Fluid Leak with a site in United States, this one is one of 2 that started in 2021, is one of 3 with no phase, and was the 7th registered.

Cerebrospinal Fluid Leak

41 studies on the registry are indexed under Cerebrospinal Fluid Leak; 9 are open to participants now.

Browse Cerebrospinal Fluid Leak studies →

Open to participants now

2 of the 12 studies in Cerebrospinal Fluid Leak with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Cerebrospinal Fluid Leak studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cerebrospinal Fluid Leak with a site in United States, or all of them as a file.
02

Study summary

The objective of the study is to clinically assess the safety and effectiveness of LIQOSEAL® as a means of reducing intra- as well as post-operative CSF leakage in patients undergoing elective cranial intradural surgery with a dural closure procedure to show noninferiority compared to a control group.

03

Conditions studied

  • Cerebrospinal Fluid Leak
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

pre-operative

  1. Subjects who are able to provide written prior to participating in the clinical investigation.
  2. Subjects who are ≥ 18 years old.
  3. Subjects who are able to comply with the follow-up or other study requirements.
  4. Subjects wo are planned for elective surgery including a trepanation to reach the subdural infratentorial space (with lower limit of incision defined as the lower edge of C2) in whom a dural incision will be closed.
  5. Female subjects of child bearing potential must agree to use a form of from the time of signing the informed consent form through 90 days post-surgery.

intra-operative

  1. Subjects with surgical wound classification Class I/Clean.
  2. Subjects with minimally 5 mm of dural space surrounding dural opening.

Exclusion criteria

Exclusion Criteria:

pre-operative

  1. Female subjects who are pregnant or breastfeeding.
  2. Subjects with an assumed impaired coagulation due to medication or otherwise.
  3. Subjects suspected of an infection requiring antibiotics.
  4. Subjects with any type of dural diseases in planned dural closure area.
  5. Subjects requiring re-opening of planned surgical area within 90 days after surgery.
  6. Subjects with a known allergy to any of the components (Lactide-Caprolactone co-polyester; Butanediol-BDI co-polyurethane; Polyethylene glycol Succinimidyl Gluterate; Disodium hydrogen phosphate or D\&C Green No 6) of LIQOSEAL®.
  7. Subjects who previously received a LIQOSEAL®.
  8. Subjects who previously participated in this study or any drug or device study within 30 days of screening.
  9. Subjects with a presence of hydrocephalus.
  10. Subjects with to MRI [cardiac pacemaker or defibrillator, severe claustrophobia, injured by a metallic object that was not removed, cochlear (ear) implants, metallic implants [e.g. knee replacement].

intra-operative

  1. Subjects in whom elevation of PEEP has a potential detrimental effect.
  2. Subjects who will require a CSF drain, electrodes or other devices passing the dural layer or extra to intracranial bypass surgery.
  3. Subjects who have primary closure of the dura mater with synthetic, nonautologous or autologous material other than galea.
  4. Subjects in whom no intra-operative CSF leakage is present after primary closure of the dura mater with elevation of PEEP.
  5. Subjects who after primary closure (including galea, if applicable) of the dura mater have a gap > 3 mm.
  6. Subjects whom dural opening size including 5 mm margin exceeds patch size (8 x 8 cm).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Investigational arm

    Application of LIQOSEAL after closure of dura mater

    Device: LIQOSEAL

  • Active comparator
    Control arm

    Application of Adherus or DurSeal after closure of dura mater

    Device: DuraSeal, Adherus

Interventions

  • DeviceLIQOSEAL

    Adjunctive bioresorbable patch

  • DeviceDuraSeal, Adherus

    synthetic absorbable sealants

06

What researchers measure

Primary outcomes

  1. Composite endpoint defined as successful dural repair without any of the following compared to the control group: intra-operative CSF leakage percutaneous CSF leak significant pseudomeningocele wound infection

    Time frame: 30 days

07

Study locations

17 sites
  • Stanford University
    Palo Alto, California 94305, United States
  • Baptist Health
    Jacksonville, Florida 32207, United States
  • Mayo Clinic
    Jacksonville, Florida 32224, United States
  • Mayo Clinic, Rochester
    Rochester, Minnesota 55905, United States
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
  • Lenox Hill Hospital
    New York, New York 10075, United States
  • University of Cincinnatti
    Cincinnati, Ohio 45229, United States
  • OHSU
    Portland, Oregon 97239, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University Hospitals of Innsbruck
    Innsbruck, Austria
  • University Hospital Gent
    Ghent, Belgium
  • Universitätsklinikum Düsseldorf
    Düsseldorf, Germany
  • UMM
    Mannheim, Germany
  • Molinette Hospital
    Torino, Italy
  • Elisabeth TweeSteden Ziekenhuis
    Tilburg, Netherlands
  • UMCU
    Utrecht, Netherlands
  • University Hospital Zurich
    Zürich, Switzerland
08

References and documents

Publications

  • Carlson AP, Slot EMH, van Doormaal TPC; ENCASE II study group; Voormolen EHJ, Dankbaar JW, Depauw P, Brouwers B, Germans MR, Baert E, Vandersteene J, Freyschlag CF, Freyschlag J, Thome C, Zenga F, Penner F, Abdulazim A, Sabel M, Rapp M, Beez T, Zuccarello M, Sauvageau E, Abdullah K, Welch B, Langer D, Ellis J, Dehdashti A, VanGompel J, Bendok B, Chaichana K, Liu J, Dogan A, Lim MK, Hayden MG. Evaluate the safety and efficacy of dura sealant patch in reducing cerebrospinal fluid leakage following elective cranial surgery (ENCASE II): study protocol for a randomized, two-arm, multicenter trial. Trials. 2022 Jul 20;23(1):581. doi: 10.1186/s13063-022-06490-8. PubMed 35858894 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Feb 2024, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2019
First posted
Sep 11, 2019
StartActual
May 20, 2021
Primary completionActual
Feb 13, 2024
CompletionActual
Feb 13, 2024
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04086550
Lead sponsor
Polyganics BV
Responsible party
Sponsor
First posted
Sep 11, 2019
Start date
May 20, 2021
Primary completion
Feb 13, 2024
Completion
Feb 13, 2024
Last update
Jun 26, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion